Home
Congress Co-Chairpersons
Welcome Note
International Advisory Board
Program
Thursday, May 03
Friday, May 04
Saturday, May 05
Sunday, May 6
Timetable
Congress Information
Faculty List
Abstract Submission
Poster Display Guidelines
CME
General Information
Partners & Links
Italian Agent
Chinese Agent
About Barcelona
List of Posters - Group A
List of Posters - Group B
Before you travel...
Registration & Accommodation
Registration
Accommodation
Princesa Sofia Hotel
Invitation letter
Sponsorship & Exhibition
Exhibition
Sponsors
Exhibitors
Sponsorship Prospectus
2011 Sponsors
Contact Us
  Scientific Program - Friday
Print

Thursday

Friday

Saturday

Sunday


 
Friday, May 4, 2012   ■  GYNECOLOGY
Session 1
08:30-10:00
CURRENT TECHNIQUES IN THE TREATMENT OF ENDOMETRIOSIS
Chairpersons: P. N Barri-Soldevila, Spain; M. Goldenberg, Israel

HALL A

Debate: Bowel resection vs. Shaving
P. Koninckx, Belgium
J. Keckstein, Austria
Tips and tricks complications
A. Ussia, Italy
Management of urinary tract endometriosis
P. Koninckx, Belgium
My technique for a faster operation          
J. Keckstein, Austria
The use of robots in endometriosis surgery
F. Nezhat, USA
 
10:00-10:30

Coffee Break at the exhibition

Session 2
10:30-12:30
CURRENT TREATMENT OPTIONS FOR UTERINE FIBROIDS
Capsule: The multidisciplinary approach for the treatment of uterine fibroids
Chairpersons: E. Loumaye, Switzerland; S. Skouby, Denmark

HALL A

10:30-11:00
Pharmacological treatment: the use of Selective progesterone receptor modulators (SPRMs)
J. Donnez, Belgium
 
 
11:00-11:25
11:25-11:50
Surgical approach
Laparoscopic vs. Hysteroscopic myomectomy for intramural fibroids
Hysteroscopic: J. Donnez,  Belgium
Laparoscopic: M. Rosati, Italy
11:50-12:10
Tips and trick for laparoscopic myomectomy
M. Rosati, Italy
12:10-12:30 Hysteroscopic intramural myomectomy
M. Goldenberg, Israel
 
12:30-13:15

 LUNCH at the exhibition

12:30-13:15 LUNCH Symposium (Gaudi Hall )
Non Invasive Monitoring of Anemia in Women Health
Sponsored by Orsense
L . Cabero, Spain; M. Hod, Israel; L. Maayan, Israel
13:15-14:30
Symposium (HALL A)
CURRENT ASSESSMENT OF PROGESTINS
Capsule: The role of progesterone in luteal support and prevention of miscarriage was well approved.
Is there a time for progestin to be added to the medical treatment formulation for these indications? 
Chairpersons:  S. Daya, Canada; R. Romero, USA
 
13:15-13:40
 
 
13:40-14:05
 
 
14:05-14:30
The use of progestational agents for luteal phase and early pregnancy support with assisted reproduction.
S. Daya, Canada
 
Progestins in Miscarriages 
G. C. Di Renzo, Italy
 
Metabolic impact of Progestins 
J. Stevenson, UK

 

 

Session 3
14:30-16:30
NEW DILEMMAS IN GYNECOLOGICAL CANCER
Capsule: Every case is a new story with a never ending debate
Chairperson: U. Beller, Israel; F. Nezhat, USA

HALL A

14:30-15:00
Differentiation between benign and malignant before surgery
L. Shulman, USA
15:00-15:30
Conservation of fertility for gynecological cancer: Principles, practice & pitfalls
U. Beller, Israel
15:30-16:00
Cancer genetic screening: It’s role in women's’ health
A. Rosenthal, UK
16:00-16:30
Primary surgery or chemotherapy for advanced ovarian cancer: A never ending story?
U. Beller, Israel
16:30-16:45
Coffee Break at the exhibition
Session 4
16:45-18:45
ORAL CONTRACEPTION: SAFETY, COMPLIANCE AND CONVENIENCE
Chairpersons: H. Coelingh Bennink, The Netherlands; L. Shulman, USA

HALL A

16:45-17:15 Should the oral contraceptive pill be stopped every month? Does the safety profile increase or decrease with non-stop administration?
S. Skouby, Denmark
17:15-17:45
The pill plus: Should this formulation replace the current use one?
H. Coelingh Bennink, The Netherlands
17:45-18:45
Panel Discussion
Chairperson: A. Ber, Israel
Discussants
J. Bitzer, Switzerland
F. Mancini, Spain
L. Shulman, USA
S. Skouby, Denmark
Q1: Vaginal bleeding during pill administration, what should be the approach?
Subscribe additional estrogen or progesterone?
Stop and start again?
Change to an OC with a higher dose of estrogen?
Change to a different pill with different progesterone formulation?
Move to vaginal ring? Patches? IUD?
Q2: Treatment of unusual conditions
Nulliparity and Intrauterine device: Time to forget  the old myths - the benefit outweighs the theoretical risks
Should we try the LNG IUS before reverting to surgery in cases of heavy menstrual bleeding?
Is the LNG IUS the best medical treatment for idiopathic heavy menstrual bleeding?
Long acting reversible contraception (LARC) should be used more freely in adolescents and nulliparous women
Hormonal contraception in obese and diabetic women, which ones should we use?
Treatment of endometrial hyperplasia with the LNG -IUS is it a good solution?
 
Friday, May 4, 2012    PERINATOLOGY
Session 5
08:30-10:00
NOVEL APPROACH TO  PRENATAL GENETIC DIAGNOSIS
Chairpersons: A. Borrell, Spain; T.H. Bui, Sweden

HALL B

08:30-08:45
Translating research into clinical practice
Non-invasive prenatal diagnosis: Analysis of cell free fetal nucleic acids
R. Chiu, China
08:45-09:00 Translating research into clinical practice
Non-invasive prenatal diagnosis: Micro RNAs
N. Shomron, Israel
09:00-09:15 The role of conventional aneuploidy markers in the era of non-invasive prenatal diagnosis
H. Cuckle, UK
09:15-09:30
The role of sonography in the NIPD era
A. Borrell, Spain
09:30-09:45 The intersection of genetic technologies and prenatal diagnosis: Where have we been and where are we going?
S. Gross, USA
09:45-10:00 Discussion
10:00-10:30

Coffee Break at the exhibition

Session 6
10:30-12:30
CONTROVERSIES TO CONSENSUS: PRENATAL GENETIC DIAGNOSIS
Chairpersons: H. Cuckle, UK; M. Evans, USA

HALL B

10:30-10:45 Critical evaluation: What is the REAL pregnancy loss due to genetic invasive testing?
M. Evans, USA
Debate:  Should invasive testing be offered to all?
10:45-11:00 Yes: We should offer testing to all: Y. Yaron, Israel 
11:00-11:15 No: M. del Campo, Spain
11:15-11:30 Discussion
Moderator: M. Evans, USA
Debate: The best antenatal diagnostic test? 
11:30-11:45 Karyotype: A. Borrell, Spain & A. Soler, Spain
11:45-12:00 CGH array: T.H Bui, Sweden
12:00-12:30 Discussion
Moderator: H. Cuckle, UK
Chairpersons' overview: Towards a consensus
The scientist: N. Shomron, Israel
The clinician: M. Evans, USA
The epidemiologist: H. Cuckle, UK
12:30-13:15 LUNCH at the exhibition
12:30-13:15 LUNCH Symposium (Gaudi Hall )
Non Invasive Monitoring of Anemia in Women Health
Sponsored by Orsense
L . Cabero, Spain; M. Hod, Israel; L. Maayan, Israel
13:15-14:30
Symposium (HALL A)
CURRENT ASSESSMENT OF PROGESTINS
Capsule: The role of progesterone in luteal support and prevention of miscarriage was well approved.
Is there a time for progestin to be added to the medical treatment formulation for these indications?
Chairpersons: S. Daya, Canada; R. Romero, USA
 
 
13:15-13:40
 
13:40-14:05
 
 
14:05-14:30
The use of progestational agents for luteal phase and early pregnancy support with assisted reproduction.
S. Daya, Canada
 
Progestins in Miscarriages
G. C. Di Renzo, Italy
 
Metabolic impact of Progestins
J. Stevenson, UK
Session 7
14:30-16:30
HOT TOPICS IN PERINATAL MEDICINE: PREGNANCY COMPLICATIONS
All you have to know in 10 minutes
Chairpersons: D. McIntyre, Australia; A. Mikhailov, Russia; U. Simeoni, France

HALL B

 
Debate: Thrombophilia and pregnancy complications: To treat or not to treat?
14:30-14:40 To treat: D. Blickstein, Israel
14:40-14:50
Not to treat: J. Bar, Israel
14:50-15:00
Discussion
Moderator: D. McIntyre, Australia
Debate: Is cerebral palsy preventable?
15:00-15:10 Hypothermia and Xenon, the success of prevention: D. Azzopardi, UK
15:10-15:20 CP is not preventable: M. Genc, USA
15:20-15:30 Discussion
Moderator: U. Simeoni, France
Debate: Cervical incompetence. Pessary or cerclage?
15:30-15:40 Pessary: M. Goya, Spain
15:40-15:50 Cerclage:  A. Antsaklis, Greece
15:50-16:00 Discussion
 
16:00-16:10
Moderator: A. Mikhailov, Russia
Q&A
16:10-16:20 Chairpersons' overview: Towards a consensus
16:30-16:45

Coffee Break at the exhibition

Session 8
16:45-18:45
THE PERINATAL TRIBUNAL
The first trimester, a window of opportunities: Screening for adverse perinatal outcome?
The Honorable Judge: G.C. Di Renzo, Italy; M. Hod, Israel

HALL B

The Case: Should all women be screened and with which test?
Maternal
Universal thyroid screening: D. McIntyre, Australia
Pre-existing diabetes: A. De Leiva, Spain
Prediction of preeclampsia: F. Figueras, Spain
Court appointed expert: G. Visser, The Netherlands
Fetal
Prediction of preterm labor: R. Romero, USA
Prediction of aneuploidy: Fetal DNA in Maternal Blood: M. Rabinowitz, USA
Prediction of aneuploidy: K. Bilardo, The Netherlands
Anatomy scan: I. Meizner, Israel
Court appointed expert: Y. Yogev, Israel
The Jury: Congress participants
The Verdict: The Honourable Judges 
 
Friday, May 4, 2012  ■  REPRODUCTIVE MEDICINE & ART
Session 9
08:30-10:00
NEW ADVANCES IN PGS
Capsule: Comprehensive chromosome analysis using microarrays is finally standardizing the genetic analysis of embryos for PGS, providing strong evidence of significant improvements in ART. However, the biopsy methods used have not yet been agreed upon, with Europe moving towards PB analysis and the Americas toward blastocyst analysis
Chairpersons: S. Fishel, UK; S. Munné, USA

HALL C

8:30-9:00 PGS using comprehensive chromosome analysis
Santiago Munne, USA
9:00-10:00 Debate: European for PBs vs. USA for blastocysts
For blastocysts: M. Hughes, USA
For PBs: K. Held, Germany
10:00-10:30
Coffee Break at the exhibition
Session 10
10:30-12:30
TREATMENT STRATEGIES FOR POOR RESPONDER PATIENTS
Capsule: Are we making any progress?
Chaipersons: Z. Shoham, Israel; A. Weissman, Israel

HALL C

10:30-11:15
Panel Discussion:
M. Dirnfeld, Israel
N. Gleicher, USA
S. Kim, USA
A. Requena, Spain
Questions
Definition: Are the new ESHRE/Bologna consensus criteria valid?
Prediction: AMH, AFC, FSH, age, which one is best?
Gonadotropin treatment: High dose, low dose or natural cycle?
To add LH or not to add LH?
GnRH agonist vs. antagonist: Which protocol to use?
Adjuvant therapy: GH, Aspirin, DHEA
Oocyte and Embryo manipulation: PGS, mitochondrial nutrients, assisted hatching?
 
SPERM EVALUATION AND SELECTION
Chairperson: M. Dirnfeld, Israel
11:15-12:25 Debate:  Current and novel concepts for sperm selection for ICSI

Sperm evaluation prior to ART: C. Chillik, Argentina

Sperm selection for ICSI: A glimpse into the new technologies: G. Huszar, USA
Not PICSI, not even IMSI:All it takes is a good embryologist: G. Verheyen, Belgium
12:25-12:30 Q&A
12:30-13:15 LUNCH at the exhibition
12:30-13:15 LUNCH Symposium (Gaudi Hall )
Non Invasive Monitoring of Anemia in Women Health
Sponsored by Orsense
L . Cabero, Spain; M. Hod, Israel; L. Maayan, Israel
13:15-14:30
Symposium  (HALL A)
CURRENT ASSESSMENT OF PROGESTINS
Capsule: The role of progesterone in luteal support and prevention of miscarriage was well approved.
Is there a time for progestin to be added to the medical treatment formulation for these indications?  
Chairpersons: S. Daya, Canada; R. Romero, USA
 
 
13:15-13:40
 
13:40-14:05
 
 
14:05-14:30
The use of progestational agents for luteal phase and early pregnancy support with assisted reproduction.
S. Daya, Canada
 
Progestins in Miscarriages
G. C. Di Renzo, Italy
 
Metabolic impact of Progestins
J. Stevenson, UK
Session 11
14:30-16:30
HOW CAN WE DIAGNOSE AND IMPROVE THE ENDOMETRIUM IN INFERTILE PATIENTS?
Capsule: The endometrial / uterine factor has neither established diagnostic criteria nor proven therapeutic options in infertile patients
Chairperson: C. Simón, Spain; N. Gleicher, USA

HALL C

14:30-14:55 Invasive diagnosis: Endometrial Receptivity Array
C. Simón, Spain
14:55-15:20
Non-invasive diagnosis in endometrial fluid
Y. Cheong, UK
15:20-15:45 Does mechanical irritation of the endometrium increase implantation rates?
Z. Shoham, Israel
15:45-16:05 Intrauterine administration of granulocyte colony-stimulating factor (G-CSF) to increase endometrial thickness.
N. Gleicher, USA
16:05-16:30 Stem cell therapy in atrophic endometrium
J. Santamaria, Spain
16:30-16:45

Coffee Break at the exhibition

Session 12
16:45-18:45
CAN YOU IMAGINE ART TODAY WITHOUT ULTRASOUND IMAGING?
Capsule: The rapid development of ultrasound technology challenges all other investigation modalities: Is this true?
Chairpersons: I. Meizner, Israel; I. Tur-Kaspa, USA

HALL C

 
16:45-17:45
Debate: Evaluation of the uterine cavity and fallopian tubes before ART. Which test to use first?
Hysteroscopy is the method of choice: M. Goldenberg, Israel
Ultrasound imaging is the preferred method: I. Tur-Kaspa, USA
Fertiloscopy is the method of choice:  A. Watrelot, France
Discussion
 
FERTILITY PRESERVATION
17:45-18:15
Ovarian reserve and stimulation in women with breast cancer: Are BRCA-mutation carriers different?
K. Oktay, USA
18:15-18:45
Fertility preservation: Practice guidelines
S. Kim, USA

Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 05/16/2012 Created by     WebStudio.co.il